Agilent Unveils AI-Enabled Cancer Research Tools at AACR 2026 — Agilent Technologies, Inc.

Event summary

Agilent will showcase new cancer research technologies at AACR 2026, including the BioTek Cytation 9 cell imaging multimode reader and AI-enhanced xCELLigence RTCA eSight software.
The company will preview its collaboration with Oxford Nanopore Technologies, integrating SureSelect target enrichment with long-read sequencing platforms.
Agilent raised $15,000 for AACR Foundation in a virtual 5K fundraiser, funding 14 Scholars-in-Training awards.
The event runs April 17–22, 2026, in San Diego, with Agilent exhibiting at booth No. 4527.

The big picture

Agilent’s focus on integrating discovery research, translational science, and companion diagnostics reflects the growing demand for seamless workflows in oncology. The company’s $6.95 billion revenue in fiscal 2025 underscores its scale, but its ability to sustain innovation will depend on strategic partnerships and AI-driven advancements. The collaboration with Oxford Nanopore Technologies highlights a broader industry trend toward hybrid-capture target enrichment and real-time sequencing.

What we're watching

AI Adoption: How Agilent’s AI-enabled software enhancements will impact the pace of cancer research and diagnostics.
Strategic Partnerships: Whether Agilent’s collaboration with Oxford Nanopore Technologies can drive further innovation in long-read sequencing.
Market Positioning: The extent to which Agilent’s integrated workflows can differentiate it in the competitive cancer research tools market.